London, UK, 21 September 2018
Edison issues outlook on Mologen (MGN)
Mologen announced that it has signed term sheets for a global partnership with Oncologie for its lead asset, lefitolimod. The deal is expected to complete in Q119, and in the near term Mologen expects to receive EUR23m from the agreement in a combination of R&D funding, cash payment and bond issues. Sensitivity remains around Oncologie who are an early stage biotech with $16m in seed funding. Mologen announced a capital raise in which it could receive gross proceeds of EUR18m. Focus remains on data from the Phase III IMPALA trial in metastatic colorectal cancer (mCRC), expected in 2020. We value Mologen at EUR188m (EUR16.6/share).
 
We value Mologen at EUR188m (EUR16.6/share) vs EUR243m previously, updated for the Oncologie deal metrics. We note that the reduction in value is driven by a lower royalty rate on net sales compared to our previous assumptions for a deal.

Click here to view the full report.
 
All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Dr Daniel Wilkinson, +44 (0)20 3077 5734
Dr Susie Jana, +44 (0)20 3077 5700
Healthcare@edisongroup.com
 
Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn        https://www.linkedin.com/company/edison-investment-research
Twitter           www.twitter.com/Edison_Inv_Res
YouTube       www.youtube.com/edisonitv